Virtu Financial’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Virtu Financial’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-80,774	Closed	-$22K	–	2564
2022 Q3	$22K	Buy	+80,774	New	+$32K	﹤0.01%	1379
2022 Q2	–	Sell	-71,475	Closed	-$49K	–	2336
2022 Q1	$49K	Buy	71,475 +54,145	+312%	+$59.4K	﹤0.01%	1144
2021 Q4	$40K	Buy	+17,330	New	+$58.6K	﹤0.01%	1395
2021 Q2	–	Sell	-23,721	Closed	-$173K	–	2297
2021 Q1	$173K	Buy	+23,721	New	+$195K	0.01%	1137

Virtu Financial's LOGC Position: Q4 2022 in Review

Virtu Financial sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 80,774 shares — an estimated $22K sold.

Virtu Financial first reported a position in LOGC in Q1 2021 and held it in 4 quarters. The position peaked at $173K in Q1 2021. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

Virtu Financial reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Virtu Financial sold 80,774 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $22K.
Virtu Financial first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
Virtu Financial's LogicBio Therapeutics, Inc. Common Stock position peaked at $173K in Q1 2021.
0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Virtu Financial's 13F filing for Q4 2022, filed 15 Feb 2023.